CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

JPMorgan Adjusts PT on Regeneron Pharmaceuticals to $950 From $900, Keeps Overweight Rating

Positive
AI Analysis

Summary

JPMorgan raised its price target on Regeneron Pharmaceuticals to $950 from $900 while maintaining an Overweight rating.

Importance:2/10
Sentiment:
0.30
price_targetanalyst_ratingequity_research
Related Companies

Read the original article

Published by yahoo_finance on October 6, 2026 10:52 AM

Read Original